The Fresh Freedom podcast will give an inside view of the representatives' work, according to organizer Rep. Eric Burlison, R-Mo.
Rep. Eli Crane and his fellow freshman members of the conservative House Freedom Caucus have started a podcast, which launched Monday.the podcast intends to give an inside view of the representatives' congressional work as well as how the Freedom Caucus functions, according to Rep. Eric Burlison, R-Mo., who organized the program.
The first episode explored the members' legislative goals, while looking back at why they ran for their positions.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Kelly Barnhill On the Love, Obligation, and Trauma at the Heart of The Crane Husband.LacyMB chats with author kellybarnhill about her latest novella TheCraneHusband, which wrestles with both contemporary themes of trauma and age-old questions of love, duty, and identity.
Read more »
Following Eli Lilly, drugmaker Novo Nordisk announces cuts to insulin pricesBREAKING: Novo Nordisk says it will lower the U.S. list price of some of its insulin products by up to 75% starting Jan. 1, 2024, following a similar move by Eli Lilly.
Read more »
Novo Nordisk plans to cut insulin prices up to 75%, following Eli LillyNovo will reduce the list price for NovoLog and NovoLog Mix 70/30 by 75%, and cut Novolin and Levemir’s list prices by 65% — but not until 2024.
Read more »
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli LillyNovo Nordisk, along with Sanofi and Eli Lilly, make up most of the U.S. insulin market.
Read more »
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli LillyNovo Nordisk is planning to slash the price of several insulin drugs by up to 75% in the U.S., following a similar move by Eli Lilly.
Read more »
Novo Nordisk to slash US insulin prices, following move by Eli LillyNovo Nordisk said on Tuesday it would cut U.S. list prices for several insulin products by up to 75% next year, joining rival Eli Lilly and Co as political pressure mounts to make these life-sustaining diabetes treatments more affordable.
Read more »